Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from March 25, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 23, 2026 — +27.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$36.00 – $38.50Entry zone — fair-value band

$37.25Published — price the day we called it

$42.84Target — the price the thesis aimed for

$47.79Peak — highest point inside the window, not a realized return

$47.42Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 36 days.

At window close

+27.3%

realized, from the publication price to the last close inside the window

Peak gain

+28.3%

peak, from the publication price — not a realized return

S&P 500, same window

+12%

SPY over the identical days, dividend-adjusted

Window close

$47.42

last close inside the window, ended June 23, 2026

Peak price

$47.79

peak on May 11, 2026 — not a realized return

Days to target

The thesis — published March 25, 2026

Predicted growth

+15%

over the measurement window

Target price

$42.84

the price the thesis aimed for

Entry zone

$36.00 – $38.50

the fair-value band we waited for

Price at publication

$37.25

published March 25, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk looks like a defensive short-term opportunity because worries in the market are already reflected in the price while the company still makes strong profits. New drug trial results for obesity and diabetes keep interest alive, and the shares seem deeply sold off rather than permanently damaged. The setup can perform even if overall markets are uneven.

Primary drivers

Trial updates for obesity and diabetes keep the growth story active
Consistently profitable business with defensive qualities
Big selloff creates space for price to bounce back
Lower valuation reduces need for perfect future growth

How it played out

NVO: target reached in 36 days

Lyra published NVO at 37.25, expecting 15% growth to 42.84. The thesis pointed to trial updates in obesity and diabetes, steady profits and defensive qualities, a large selloff that left room for a rebound, and a lower valuation. It expected the setup to hold up in uneven markets.

Inside the window, NVO reached 42.84 in 36 days. It later peaked at 47.79 on May 11, a 28.3% gain from publication. The shares ended the window at 47.42, still above the target. The published thesis played out fully, and the market outcome exceeded the expected 15% rise.

What happened during the window

On April 23, Novo Nordisk reported positive topline results from its PIONEER TEENS trial. On May 6, the company reported its first-quarter results and raised its 2026 guidance for adjusted sales and adjusted operating profit.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals